Oculis Holding (OCS) Price & Analysis

Compare

74 Followers

OCS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$11.90 - $23.08

Previous CloseN/A

Volume95.89K

Average Volume (3M)11.91K

Market Cap

$948.89M

Enterprise Value$814.84M

Total Cash (Recent Filing)$160.30M

Total Debt (Recent Filing)$1.03M

Price to Earnings (P/E)―

Beta0.47

Next Earnings

Nov 06, 2025

EPS Estimate

-0.52

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.61

Shares Outstanding54,533,672

10 Day Avg. Volume13,602

30 Day Avg. Volume11,913

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.86

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-7.67

Forecast

1Y Price Target

$33.00

Price Target Upside89.66% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical TrialsEnrollment for the pivotal phase 3 trials of OCS-01 in DME is complete, keeping the program on track for a key topline data readout.

Financial HealthWith cash runway extended into early 2028, Oculis is well-funded through key data catalysts.

Product DevelopmentOCS-01 aims to be the first non-invasive therapy for DME, potentially expanding the market to patients who typically go untreated.

Bears Say

Market VisibilityOculis is considered an under-the-radar story that is approaching a data-rich period, suggesting potential for future developments.

Product RiskOCS-02 offers a biologic mechanism of action for dry-eye disease through eye drops, with a precision medicine-based approach to reduce risk in phase 3 development.

Oculis Holding News

Oculis initiated with a Buy at Needham

Needham initiated coverage of Oculis (OCS) with a Buy rating and $36 price target Lead-asset OCS-01 aims to...

24d ago

OCS

Nvidia reportedly stops H20 AI chip output for China: Morning Buzz

The major averages were sharply higher near noon as U.S. Federal Reserve Chair Jay Powell said in his...

29d ago

Oculis price target raised to $33 from $32 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Oculis (OCS) to $33 from $32 and keeps a Buy...

29d ago

OCS

Oculis reports Q2 EPS (49c), consensus (43c)

Riad Sherif, CEO of Oculis (OCS), stated: “We maintain a strong focus on execution to advance our portfolio...

29d ago

OCS

Oculis Holding: Buy Rating Backed by Strong Financials and Promising Clinical Pipeline

In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Oculis...

29d ago

OCS

Oculis Holding AG Reports Q2 2025 Financial Progress

Oculis Holding Ag ( ($OCS) ) has released its Q2 earnings. Here is a breakdown of the information...

29d ago

OCS

Oculis Holding Reports Strong Financial Position in Mid-2025

Oculis Holding ( ($OCS) ) has shared an announcement. On August 21, 2025, Oculis Holding AG announced its...

29d ago

OCS

OCS Upcoming Earnings Report: What to Expect?

Oculis Holding Ag (OCS) is scheduled to report 2nd quarter earnings on 08/19/2025. Regarding Q2 estimates, Wall Street...

1M ago

OCS

Oculis Holding AG Secures Amended Loan Agreement with Kreos Capital

Oculis Holding ( ($OCS) ) has issued an update. Oculis Holding AG, a company based in Zug, Switzerland,...

2M ago

OCS

Oculis Holding AG Announces 2025 AGM Results and Strategic Approvals

Oculis Holding ( ($OCS) ) has shared an update. On June 5, 2025, Oculis Holding AG announced the...

4M ago

OCS

Oculis Holding’s Promising Pipeline and Strategic Initiatives Drive Buy Rating

Oculis Holding (OCS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

4M ago

OCS

Oculis Announces 2025 Annual General Meeting Details

Oculis Holding ( ($OCS) ) has shared an update. On May 9, 2025, Oculis Holding AG announced the...

4M ago

OCS

Oculis Holding AG Reports Strong Q1 Progress

Oculis Holding Ag ( ($OCS) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

OCS

Oculis Holding AG Reports Q1 2025 Financial Results

An announcement from Oculis Holding ( ($OCS) ) is now available. On May 8, 2025, Oculis Holding AG...

4M ago

OCS

OCS FAQ

What was Oculis Holding’s price range in the past 12 months?

Oculis Holding lowest stock price was $11.90 and its highest was $23.08 in the past 12 months.

What is Oculis Holding’s market cap?

Oculis Holding’s market cap is $948.89M.

When is Oculis Holding’s upcoming earnings report date?

Oculis Holding’s upcoming earnings report date is Nov 06, 2025 which is in 47 days.

How were Oculis Holding’s earnings last quarter?

Oculis Holding released its earnings results on Aug 21, 2025. The company reported -$0.612 earnings per share for the quarter, missing the consensus estimate of -$0.512 by -$0.1.

Is Oculis Holding overvalued?

According to Wall Street analysts Oculis Holding’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oculis Holding pay dividends?

Oculis Holding does not currently pay dividends.

What is Oculis Holding’s EPS estimate?

Oculis Holding’s EPS estimate is -0.52.

How many shares outstanding does Oculis Holding have?

Oculis Holding has 54,533,672 shares outstanding.

What happened to Oculis Holding’s price movement after its last earnings report?

Oculis Holding reported an EPS of -$0.612 in its last earnings report, missing expectations of -$0.512. Following the earnings report the stock price went up 0.281%.

Which hedge fund is a major shareholder of Oculis Holding?

Currently, no hedge funds are holding shares in OCS

Oculis Holding Stock Smart Score

Neutral

Fundamentals

Return on Equity

-80.98%

Trailing 12-Months

Asset Growth

47.79%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oculis Holding

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Oculis Holding (OCS) Earnings & Revenues

Historic Earnings Reports

OCS Stock 12 Month Forecast

Average Price Target

$33.00

▲(89.66% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","37":"$37","16.75":"$16.75","23.5":"$23.5","30.25":"$30.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,16.75,23.5,30.25,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.15,17.676923076923075,19.203846153846154,20.73076923076923,22.257692307692306,23.784615384615385,25.31153846153846,26.838461538461537,28.365384615384613,29.892307692307693,31.41923076923077,32.94615384615385,34.473076923076924,{"y":36,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.15,17.446153846153845,18.74230769230769,20.038461538461537,21.334615384615383,22.63076923076923,23.926923076923075,25.223076923076924,26.519230769230766,27.815384615384616,29.11153846153846,30.407692307692308,31.703846153846154,{"y":33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.15,17.06153846153846,17.97307692307692,18.884615384615383,19.796153846153846,20.707692307692305,21.619230769230768,22.53076923076923,23.442307692307693,24.353846153846153,25.265384615384615,26.176923076923075,27.088461538461537,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.85,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.76,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.45,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.09,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.73,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.7,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.15,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >